Retail investors looking to build long-term wealth should think carefully before placing bets on the Metropolitan Stock ...

C3.ai, Inc. faces revenue quality issues, management churn, and cash burn with acquisition rumors providing modest upside.

Summit Therapeutics nears a 2026 FDA decision for ivonescimab with $710M cash and Akesobio catalysts. Find out why SMMT stock is upgraded to hold.

In special education in the U.S., funding is scarce and personnel shortages are pervasive, leaving many school districts ...

Almost three of every four restaurant orders in the U.S. weren’t eaten in a restaurant, according to recent data. We spoke to ...